Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

52.50 +0.25 (+0.48%)

Delayed Quote Updated: 11:58 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2

...

17 18 19 20 21 22 23 24 25

...

38 39 Next >

FDA Approves Genentech’s Polivy in Combination With R-CHP for People With Certain Types of Previously Untreated Diffuse Large B-cell Lymphoma

April 19, 2023

From Genentech

Via Business Wire

Genentech’s Tecentriq Plus Avastin Reduced the Risk of Cancer Returning in People With Certain Types of Adjuvant Liver Cancer in a Phase III Study

April 16, 2023

From Genentech

Via Business Wire

EXCLUSIVE: FDA Grants Expedited Review Status To SAB Biotherapeutics' Influenza Antibody ↗

April 13, 2023

The FDA has granted Fast Track designation for SAB Biotherapeutics' (NASDAQ: SABS) SAB-176, an investigational therapeutic for Type A and Type B influenza illness in high-risk patients, including those...

Via Benzinga

Is Roche a Buy Now? ↗

March 20, 2023

Roche focuses on the long-term.

Via The Motley Fool

Trillions In Biotech Stock Gains Trace Back To This Financier ↗

April 13, 2023

Frank did not grow up as son of a Wall Street banker. He began as the consummate outsider.

Via Investor's Business Daily

Genentech Data Highlights Strength of Ophthalmology Portfolio and Commitment to Advancing Eye Care at ARVO 2023

April 13, 2023

From Genentech

Via Business Wire

Why Shares of Adaptimmune Therapeutics Jumped Tuesday ↗

April 11, 2023

The company bulks up its pipeline by regaining the rights to two of its clinical programs.

Via The Motley Fool

Top-Notch Biotech TG Therapeutics Logs 'Solid Jump' In Sales; Shares Rocket ↗

April 10, 2023

Shares are closing in on a buy point out of a consolidation.

Via Investor's Business Daily

Bolt Biotherapeutics Says Phase 1 Data Supports Advancing Into Phase 2 Studies ↗

March 30, 2023

Via Benzinga

Roche's Slow Growth Shouldn't Drive Investors Away ↗

March 28, 2023

New treatments for various cancers, eye diseases, and more may bring in future revenues.

Via The Motley Fool

Roche Joins Hand With Lilly To Improve Early Diagnosis Of Alzheimer's Disease ↗

March 22, 2023

Via Benzinga

New Four Year Data For Roche's Evrysdi Reinforces Long-Term Efficacy, Safety Profile In Muscular Atrophy Patients ↗

March 20, 2023

Via Benzinga

New Four-Year Data for Genentech’s Evrysdi Reinforce Long-Term Efficacy and Safety Profile in Some of the Most Severely Affected People With Types 2 and 3 Spinal Muscular Atrophy (SMA)

March 20, 2023

From Genentech

Via Business Wire

Sarepta Plunges As FDA Takes Surprise Turn; AdComm Meeting Set For Duchenne Gene Therapy ↗

March 17, 2023

Via Benzinga

Daily Stock Analysis: Roche Holding AG ↗

March 16, 2023

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was...

Via Talk Markets

Biotech Sector Working Fast to Combat Alzheimer’s Disease Cases That are Set to Explode

March 15, 2023

FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 15, 2023 – USA News Group – According to a 2022 study of more than 6 million patients 65 and older, the risk factor for...

Via FinancialNewsMedia

FDA Advisory Committee Votes in Favor of the Clinical Benefit of Genentech's Polivy Combination for People With Previously Untreated Diffuse Large B-Cell Lymphoma

March 09, 2023

From Genentech

Via Business Wire

FDA Casts Doubts Over Roche's Polivy Label Expansion For Untreated Lymphoma Setting ↗

March 09, 2023

Via Benzinga

The Top 7 Growth Stocks in Biotech ↗

March 03, 2023

The biotech sector always houses a great selection of growth stocks that can grow rapidly and reward investors over the long-term.

Via InvestorPlace

Roche, Exelixis Report Second Flop Out Of Three Trials Evaluating Cabozantinib/Atezolizumab Combo ↗

March 03, 2023

Via Benzinga

Why Sarepta Therapeutics' Shares Rose 23.4% This Week ↗

March 02, 2023

The company's latest Duchenne muscular dystrophy gene therapy may have an accelerated approval.

Via The Motley Fool

3 Best Growth Stocks to Buy In March ↗

March 02, 2023

These three red-hot growth stocks have more room to run.

Via The Motley Fool

Blueprint Medicines Highlights Detailed Data From Lead Product In Blood Cancer Patients ↗

February 27, 2023

Via Benzinga

Roche Decides To Terminate Cancer Treatment Pact With Blueprint Medicines ↗

February 23, 2023

Via Benzinga

Infinity Pharmaceuticals Announce Merger Agreement With MEI Pharma, Share Plunge ↗

February 23, 2023

Via Benzinga

Apellis Surges To Four-Month High — Sending Rival Iveric Tumbling — On A First-Ever Approval ↗

February 21, 2023

Apellis is soon to launch its newest drug, Syfovre, for geographic atrophy patients.

Via Investor's Business Daily

Biogen Beats Q4 Earnings & Sales Estimates, Stock Up ↗

February 15, 2023

Biogen reported fourth-quarter 2022 adjusted earnings per share (EPS) of $4.05.

Via Talk Markets

New Data Shows Roche's Vabysmo Improves Vision, Retinal Fluid In Retinal Disorder ↗

February 10, 2023

Via Benzinga

New Phase III Data Show Genentech’s Vabysmo Rapidly Improved Vision and Reduced Retinal Fluid in People With Retinal Vein Occlusion (RVO)

February 10, 2023

From Genentech

Via Business Wire

Roche Touts Positive Crovalimab Data From Late-Stage Study In Rare Blood Condition ↗

February 07, 2023

Via Benzinga

< Previous 1 2

...

17 18 19 20 21 22 23 24 25

...

38 39 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.